Psychiatric Disorders and Psychopharmacology
This track delves into the complex neurobiology of psychiatric illnesses, including depression, bipolar disorder, anxiety, schizophrenia, and PTSD. Attendees will explore how imbalances in neurotransmitter systems such as serotonin, dopamine, and norepinephrine influence mood and behaviour. Psychopharmacology sessions will focus on the development and clinical use of antidepressants, antipsychotics, mood stabilizers, and anxiolytics. The track will highlight recent advancements in pharmacogenomics, personalized medicine, and the role of neuroinflammation in psychiatric pathology. Cutting-edge research on psychedelic-assisted therapy and novel targets like ketamine will also be presented. This track is vital for anyone interested in the evolving landscape of mental health treatment.